Coexpression of major histocompatibility complex class I and LMP1 in Epstein-Barr virus-positive Hodgkin's lymphoma in a pediatric age group.

The Epstein-Barr virus (EBV)-encoded latent membrane proteins (LMP1 and LMP2) are consistently expressed by malignant Hodgkin Reed-Sternberg (HRS) cells of EBV-associated Hodgkin's disease (HD). The EBV LMP1 has been implicated in tumorogenesis. Cytotoxic T lymphocyte (CTL) responses to both of these proteins have been shown in the blood of EBV-seropositive individuals, and in HD, the apparent failure of the CTL response to eliminate HRS cells expressing LMP1 in vivo has given rise to the suggestion that HD may be characterized by the presence of defects in antigen CTL-presentation or in CTL dysfunction. This study examined 28 cases seen at the Regional Children's Hospital Arturo Grullón in Santiago, the Dominican Republic, by immunohistochemistry. High level of expression of major histocompatibility complex (MHC) class I molecules in HRS cells of EBV-associated HD was recorded. These results suggest that deregulation of MHC class I molecules does not account for the apparent ability of EBV to infect HRS cells and to evade CTL protection. Therefore, the result from our work and similar studies will help to determine whether, or which, immunotherapy should be used in positive and negative cases of HD related to EBV.